Lilly's latest pipeline peril, Mylan's M&A broken record, and German Merck's big rebrand

Fierce editors discuss a major blow to Eli Lilly's late-stage pipeline, Mylan's ongoing courtship of Perrigo, and Merck KGaA's big push to distance itself from that other Merck.